Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth

Anticancer Research

Volumn 19, Issue 4 A, 1999, Pages 2661-2663

  Hautmann, Stefan Hans ^a,b   Huland, Edith ^a   Huland, Hartwig ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Immunotherapy; Interleukin 2; Locally advanced; Prostate cancer

Indexed keywords

GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; EXPERIMENTAL NEOPLASM; INTRATUMORAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RAT; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DRUG IMPLANTS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; MALE; PROSTATIC NEOPLASMS; RATS;

EID: 0032809709     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Henriksson R, Widmark A, Bergh A and Damber JE: Interleukin-2-induced growth inhibition of prostatic adenocarcinoma (Dunning R3327) in rats. Urol Res 20: 189-191, 1992.
2. Lotze MT, Montory YL and Rayner AA: Clinical effects and toxicity of interleukin 2 in patient with cancer. Cancer 58: 2764-2772, 1986.
3. Queseda JR, Swanson DA and Trindade A: Renal cell carcinoma: antitumor effects of leucocytes interferon. Cancer Res 43: 940-947, 1983.
4. Rosenberg SA: Lymphokin-activated-killer-cells: A new approach to immunotherapy of cancer. J Natl Cancer Inst 75: 5959-603, 1985.
5. West WH, Tauer KW and Vanelli JR: Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898-905, 1987.
6. Rosenberg SA, Lotze MT and Muul LM: A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 alone. N Engl J Med 316: 889-897, 1987.
7. Bubenik J: Local and regional immunotherapy of cancer with interleukin 2 (guest editorial). J Cancer Res Clin Oncol 116: 1-7, 1990.
8. Huland E, Falk B, Hübner D and Huland H: In vivo system to detect long term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors. J Cancer Res Clin Oncol 121: 285-290, 1995.
9. Huland E and Huland H: Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49: 5469-5474, 1989.
10. Huland E, Heinzer H and Huland H: Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon a in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J Cancer Res Clin Oncol 120: 221-228, 1994.
11. Huland E, Huland H and Heinzer H: Interleukin 2 by inhalation: local therapy for metastatic renal cell carcinoma. J Urol 147: 344-348, 1992.
12. Osieka R, Becker R and Schmidt CG: Molecular pharmacology on human cancer xenografts. In: Bastert G, Fortmeyer HP and Schmidt-Matthhiesen H (eds) Thymus aplastic nude mice and rats in clinical oncology. Fischer, Stuttgart New York, 1981, pp 513-525.